SOPHIA ANTIPOLIS, France – October 17, 2025 │ This quarter, KnowMade’s Therapeutic mRNA patent monitoring service reveals two emerging players shaping the next wave of RNA innovation: Parcel Bio, pioneering nanoparticle-free delivery, and ArkeaBio, developing mRNA vaccines for methane mitigation. Two Emerging Players Expand the Frontiers of Therapeutic mRNA Innovation Two new entrants have emerged[…]
SOPHIA ANTIPOLIS, France – July 16, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring service. What’s new today? Spotlight on Emerging Innovators: The Strategic Value of Patent Monitoring The first half of 2025 confirms the ongoing momentum in therapeutic mRNA innovation, as highlighted in KnowMade’s press release[…]
SOPHIA ANTIPOLIS, France – July 11, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring service. What’s new today? Emerging Innovators in a Record-Setting Quarter for Therapeutic mRNA The continued innovation in therapeutic mRNA is confirmed through the first half of 2025, as reflected by KnowMade’s Therapeutic mRNA[…]
SOPHIA ANTIPOLIS, France – July 10, 2025 │ In July, Regeneron received accelerated approval from the FDA for its bispecific antibody (bsAb) Linvoseltamab (brand name Lynozyfic). It is intended to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least 4 prior lines of therapy, including a proteasome inhibitor,[…]